Sodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors in the Management Of Type-2 Diabetes: A Drug Class Overview

P T. 2015 Jul;40(7):451-62.

Abstract

Sodium-glucose linked transporter 2 inhibitors limit the reabsorption of glucose from glomerular filtrate in the kidneys, reducing blood glucose levels in patients with type- 2 diabetes. This article is meant to evaluate this class of medications for clinicians.

Keywords: canagliflozin; dapagliflozin; empagliflozin; sodium-glucose linked transporter 2 (SGLT2) inhibitors; type-2 diabetes mellitus (T2DM).